

# Estela Paz-Artal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2704137/publications.pdf>

Version: 2024-02-01

53  
papers

1,571  
citations

411340

20  
h-index

406436

35  
g-index

55  
all docs

55  
docs citations

55  
times ranked

2935  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution. <i>Biomedicines</i> , 2022, 10, 296.	1.4	25
2	Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, , .	1.5	7
3	Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers. <i>Cancer Immunology Research</i> , 2022, 10, 498-511.	1.6	12
4	Novel genes and sex differences in COVID-19 severity. <i>Human Molecular Genetics</i> , 2022, 31, 3789-3806.	1.4	38
5	T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 624483.	1.8	110
6	Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study. <i>International Journal of Infectious Diseases</i> , 2021, 105, 319-325.	1.5	10
7	Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study. <i>International Journal of Infectious Diseases</i> , 2021, 105, 487-494.	1.5	11
8	Next Generation Sequencing for Detecting Somatic FAS Mutations in Patients With Autoimmune Lymphoproliferative Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 656356.	2.2	12
9	Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 667515.	2.2	16
10	IL-6-based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1652-1661.e1.	1.5	14
11	T cell-mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19. <i>American Journal of Transplantation</i> , 2021, 21, 2785-2794.	2.6	17
12	Circulatory follicular helper T lymphocytes associate with lower incidence of CMV infection in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3946-3957.	2.6	5
13	Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management. <i>Frontiers in Immunology</i> , 2021, 12, 671755.	2.2	35
14	Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS). <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 253-274.	2.7	14
15	SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1258-1262.	1.6	3
16	Discordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients. <i>Transplantation Direct</i> , 2021, 7, e794.	0.8	28
17	The Weight of IgA Anti- $\beta$ 2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8972.	1.8	23
18	IL-6-based mortality risk model for hospitalized patients with COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 799-807.e9.	1.5	154

#	ARTICLE	IF	CITATIONS
19	Imbalance favoring follicular helper T cells over IL10+ regulatory B cells is detrimental for the kidney allograft. <i>Kidney International</i> , 2020, 98, 732-743.	2.6	13
20	IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection. <i>Annals of Hematology</i> , 2020, 99, 2953-2956.	0.8	7
21	Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients. <i>Transplantation</i> , 2020, 104, 2599-2608.	0.5	8
22	Longitudinal profile of circulating T follicular helper lymphocytes parallels anti-HLA sensitization in renal transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 89-97.	2.6	48
23	Post-transplant hypocomplementemia: A novel marker of cardiovascular risk in kidney transplant recipients?. <i>Atherosclerosis</i> , 2018, 269, 204-210.	0.4	2
24	The Presence of Pretransplant Antiphospholipid Antibodies IgA Anti- $\beta$ 2-Glycoprotein I as a Predictor of Graft Thrombosis After Renal Transplantation. <i>Transplantation</i> , 2017, 101, 597-607.	0.5	34
25	$\beta$ 2-Glycoprotein I/IgA Immune Complexes. <i>Circulation</i> , 2017, 135, 1922-1934.	1.6	30
26	5-gene differential expression predicts stability of human intestinal allografts. <i>Experimental and Molecular Pathology</i> , 2017, 103, 163-171.	0.9	3
27	Acquired Senescent T-Cell Phenotype Correlates with Clinical Severity in GATA Binding Protein 2-Deficient Patients. <i>Frontiers in Immunology</i> , 2017, 8, 802.	2.2	18
28	Incidence of thromboembolic events in asymptomatic carriers of IgA anti $\beta$ 2 glycoprotein-I antibodies. <i>PLoS ONE</i> , 2017, 12, e0178889.	1.1	54
29	High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation. <i>International Immunology</i> , 2016, 28, 55-64.	1.8	19
30	Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 1242-1253.	0.9	32
31	Isolated De Novo Antiendothelial Cell Antibodies and Kidney Transplant Rejection. <i>American Journal of Kidney Diseases</i> , 2016, 68, 933-943.	2.1	8
32	Monitoring of intracellular adenosine triphosphate in CD4 <sup>+</sup> T cells to predict the occurrence of cytomegalovirus disease in kidney transplant recipients. <i>Transplant International</i> , 2016, 29, 1094-1105.	0.8	11
33	Low Natural Killer Cell Counts and Onset of Invasive Fungal Disease After Solid Organ Transplantation. <i>Journal of Infectious Diseases</i> , 2016, 213, 873-874.	1.9	14
34	Blockade of cell adhesion molecules enhances cell engraftment in a murine model of liver cell transplantation. <i>Transplant Immunology</i> , 2016, 35, 7-11.	0.6	1
35	High proportion of CD95+ and CD38+ in cultured CD8+ T cells predicts acute rejection and infection, respectively, in kidney recipients. <i>Transplant Immunology</i> , 2016, 34, 33-41.	0.6	12
36	High expression of CD38, CD69, CD95 and CD154 biomarkers in cultured peripheral T lymphocytes correlates with an increased risk of acute rejection in liver allograft recipients. <i>Immunobiology</i> , 2016, 221, 595-603.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Early renal graft function deterioration in recipients with preformed anti-MICA antibodies: partial contribution of complement-dependent cytotoxicity. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 150-160.	0.4	19
38	Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation. <i>Immunobiology</i> , 2016, 221, 40-47.	0.8	25
39	Detection of circulating immune complexes of human IgA and beta 2 glycoprotein I in patients with antiphospholipid syndrome symptomatology. <i>Journal of Immunological Methods</i> , 2015, 422, 51-58.	0.6	21
40	Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to $\beta$ 2-Glycoprotein I. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 735-745.	3.0	31
41	Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation. <i>Pediatric Research</i> , 2015, 78, 603-608.	1.1	21
42	Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation. <i>Transplant International</i> , 2014, 27, 674-685.	0.8	65
43	Isolated IgA Anti- $\beta$ 2 Glycoprotein I Antibodies in Patients with Clinical Criteria for Antiphospholipid Syndrome. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	0.9	68
44	Renal Transplantation Dramatically Reduces IgA Anti-beta-2-glycoprotein I Antibodies in Patients with Endstage Renal Disease. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	24
45	Comparison of several functional methods to evaluate the immune response on stable kidney transplant patients. <i>Journal of Immunological Methods</i> , 2014, 403, 62-65.	0.6	7
46	A case of partial dedicator of cytokinesis 8 deficiency with altered effector phenotype and impaired CD8+ and natural killer cell cytotoxicity. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 218-221.e7.	1.5	12
47	Heterogeneity between Diagnostic Tests for IgA anti-Beta2 Glycoprotein I: Explaining the Controversy in Studies of Association with Vascular Pathology. <i>Analytical Chemistry</i> , 2013, 85, 12093-12098.	3.2	31
48	IgA antibodies against $\beta$ 2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. <i>Kidney International</i> , 2012, 81, 1239-1244.	2.6	60
49	Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes. <i>Journal of Leukocyte Biology</i> , 2008, 84, 488-498.	1.5	17
50	The induction of Bim expression in human T-cell blasts is dependent on nonapoptotic Fas/CD95 signaling. <i>Blood</i> , 2007, 109, 1627-1635.	0.6	25
51	Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation. <i>Immunobiology</i> , 2007, 212, 73-83.	0.8	17
52	A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. <i>Blood</i> , 2006, 108, 1306-1312.	0.6	117
53	Transcription and weak expression of HLA-DRB6 : a gene with anomalies in exon 1 and other regions.. <i>Immunogenetics</i> , 1998, 48, 16-21.	1.2	15